<DOC>
	<DOCNO>NCT01993446</DOCNO>
	<brief_summary>The purpose study determine whether DRM02 safe effective treatment rosacea apply twice daily 6 week .</brief_summary>
	<brief_title>A Safety Efficacy Study DRM02 Subjects With Rosacea</brief_title>
	<detailed_description>This double-blind , randomize , vehicle control , study enrol 30 subject rosacea design assess safety , tolerability , preliminary efficacy DRM02 . Safety assess study , adverse event , local skin response , urinalysis , serum chemistry hematology laboratory testing , physical examination vital sign . Preliminary efficacy assess inflammatory lesion count , Investigator 's Global Evaluation ( IGE ) Rosacea Signs Symptoms ( RSS ) scale .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<criteria>Male female 18 70 year age . Clinical diagnosis rosacea score 2 3 Investigator 's Global Evaluation ( IGE ) Rosacea scale least 15 40 papule . Subjects willing minimize external factor might trigger rosacea flareups . Male nonpregnant , nonlactating female . Signed informed consent . Severe selfreported facial sensitivity . Severe sun sensitivity . Ocularonly , phymatous rosacea steroid rosacea . Use topical rosacea treatment 4 week prior baseline . Use systemic corticosteroid within 4 week prior baseline . Use systemic antibiotic 4 week prior baseline . Use systemic retinoids 6 month prior baseline . Use topical retinoids 3 month prior baseline . Use light laserbased rosacea treatment past 2 month prior baseline . Cosmetic procedure within 2 month prior baseline . Use topical antiaging medication 2 week prior baseline . Subjects poor skin condition within 5 cm treatment area . Subjects current drug alcohol abuser ; history immunodeficiency poor medical risk systemic disease active uncontrolled infection . Subjects unstable medical condition medical condition adequately control standard medical therapy . Subjects actively participate experimental therapy study receive experimental therapy within 30 day . Subjects clinically significant laboratory value screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>